GLP-1 drugs like Ozempic and Wegovy are reshaping employer drug spend. Coverage decisions come down to weighing rising costs against outcomes, employee demand, and competitive benefits positioning. Most employers are moving toward conditional coverage models rather than blanket exclusion or inclusion.
If one headline has taken over the HR and benefits world in the past two years, it’s been the impact of GLP-1s on healthcare spending. Demand for popular new weight loss drugs like Ozempic and Wegovy is rising by the day, with no signs of stopping. But for employers, these drugs are also raising questions that are a lot more complicated than “to cover or not to cover.”
GLP-1 medications have gone from relatively niche diabetes treatments to one of the biggest conversations in healthcare. Employees are asking about them. Prescriptions are growing. And the exponentially rising cost to employers is hard to ignore.
At the same time, employers are facing a much bigger quandary: What does responsible GLP-1 coverage look like when you’re balancing employee needs with a very real impact on your benefits budget?
Here’s what your organization should know about GLP-1 coverage in 2026—and where a strong benefits communication strategy can help.
What is driving GLP-1 demand in the workplace?
You’re not dreaming: everyone (and their mother) is talking about GLP-1s.
GLP-1 stands for glucagon-like peptide-1, a hormone that regulates blood sugar and appetite. Medications in this class include drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. While some GLP-1 medications were originally developed to treat type 2 diabetes, several are now FDA-approved for chronic weight management and other conditions.
That means a much broader group of people are eligible to use GLP-1s, and doctors have a huge new opportunity to prescribe them. While nearly half of Americans qualify, only 1 in 8 are currently using a GLP-1. But usage is predicted to only increase in the next few years.
Another simple reason that GLP-1 demand is rising? Employees are asking for it.
Thanks to the drug’s widespread popularity, Americans are curious about how a GLP-1 might help them, and they’re approaching their healthcare providers about it, instead of waiting for their doctor to bring it up.
These conversations aren’t just popping up at the doctor’s office, either. New data shows that access to GLP-1s (or lack thereof) is affecting employees’ relationships with their employer, too. In fact, over a quarter of employers now say that covering GLP-1s is “very important” to their employees’ satisfaction with their health plan, with another 37% saying it’s “important.”
So there’s a balancing act underway: employees want access to medications that may meaningfully affect their health. And employers need to understand what that access could mean for their benefits budget.
What do GLP-1 drugs cost employers?
The story that usually follows any conversation about GLP-1’s rise in popularity? How expensive they are.
Mercer recently reported that GLP-1 medications used to treat diabetes and obesity are having a significant impact on prescription drug costs. They also found that over three-quarters of employers consider managing GLP-1 costs an extremely or very important priority.
For employers, that spending can add up quickly.
In fact, GLP-1 drugs used for weight loss represented an average of 11.4% of total annual claims in 2025. For context, only cancer and musculoskeletal disorders surpass that percentage among the biggest claims drivers. So GLP-1s have quickly made a significant dent in employers’ healthcare spending.
That doesn’t mean every employer is spending 11.4% of its benefits budget on GLP-1s. That survey figure is based on total annual claims among participating employers who cover these medications, and employer populations and plan designs vary. But it illustrates why GLP-1 spending has become a significant C-suite conversation.
And there’s another wrinkle. Utilization can be higher than employers expect:
- 44% of firms with 1,000–4,999 workers and 59% of firms with 5,000+ workers said GLP-1 utilization was higher than expected.
- 43% of firms with 1,000–4,999 workers and 66% of firms with 5,000+ workers said GLP-1 coverage had a “significant” impact on the health plan’s prescription drug spending.
Of course, the high upfront cost of covering weight-loss drugs is enough to give any employer pause. But organizations shouldn’t overlook one potential upside: the health benefits GLP-1s may offer could bring savings down the road.
We’re learning that GLP-1 medications may affect more than weight. Depending on the medication and the individual’s health circumstances, they can play a role in managing other conditions associated with morbid obesity and cardiometabolic health. And healthier employees could mean lower claims costs in the future.
But those long-term financial impacts are still an evolving question, and employers shouldn’t assume those future savings will automatically offset today’s pharmacy costs.
That’s why the best question your organization should be asking itself right now is, “What will GLP-1 coverage cost us now, who will use it, and what outcomes can we reasonably expect?”
How are other employers approaching coverage?
There’s no single GLP-1 playbook for employers. Some cover new weight loss drugs like Ozempic and Wegovy. Others exclude them. And some fall in between, using eligibility requirements or utilization-management strategies to determine who qualifies.
In other words, the question isn’t always whether to cover GLP-1s. It’s also how to structure that coverage.
For an accurate look at the current landscape, let’s take a look at some data that illustrates how employers are tackling the GLP-1 coverage question:
- 36% of employers currently cover GLP-1 drugs for both diabetes and weight loss.
- Among employers that cover these medications, eligibility requirements are common: 90% use a minimum BMI requirement, 54% require obesity plus another chronic condition, and 29% require participation in a lifestyle-modification program.
Prior authorization is another common tool employers use to offer GLP-1 coverage while tempering spending.
Together, these strategies can help employers make weight loss drugs accessible to their workforce without eliminating coverage completely. If you’re thinking about adding GLP-1 coverage to your benefits offerings next year, here’s a quick list of considerations that you might bring to your C-suite:
Potential cost-saving strategies for employers who offer GLP-1 coverage
- Prior authorization: Employees need approval before the plan covers the medication.
- Eligibility requirements: Coverage may depend on factors like BMI or other health conditions.
- Lifestyle or weight-management programs: Employees may need to participate in additional programs alongside medication.
- Selective coverage: A plan may cover certain GLP-1 medications while excluding others.
- Ongoing authorization: Employees may need to demonstrate continued eligibility for coverage over time.
Takeaway: There’s no universal formula here. What makes sense for a 500-person company may look very different for a 50,000-person employer.
How will employers’ approach to GLP-1 coverage continue to evolve?
While employers have been quick to jump on the GLP-1 wagon to meet the moment and support employees’ health needs, research also shows they’re already reassessing their approach.
Expensive claims costs and higher-than-expected usage mean some employers plan to drop coverage in the years ahead.
of employers dropped their GLP-1 coverage in 2026
of employers plan to drop their coverage in 2027
of employers tightened their GLP-1 utilization controls in 2026 or plan to do so in 2027
That highlights an important message for benefits teams: your GLP-1 strategy isn’t a “set it and forget it” decision.
As utilization changes, new medications enter the market, prices and rebates shift, and evidence around long-term outcomes develops, your organization may need to revisit its coverage strategy.
And with every change comes another challenge: making sure employees understand what a shift in coverage actually means for them.
How can benefits communication tools help employees navigate this decision?
If we’ve learned anything so far, it’s that no two employers offer GLP-1s the same way, and there’s still a lot to learn about how these new drugs fit into your company’s overall benefits strategy.
And if your HR team is still figuring things out, that means your employees are too. As more and more folks consider using drugs like Ozempic and Wegovy, they’re going to need extra guidance to figure out what’s covered and what’s not.
But employees don’t necessarily need another 47-page PDF explaining their prescription benefits. They need to understand which GLP-1 is right for them, what eligibility requirements they may need to meet, and when they’ll need to seek prior authorization.
And that’s all too complicated to break down succinctly in a benefits guide—much less in a personalized way. That’s where a benefits decision support tool like ALEX can help make a complicated experience a lot more manageable.
ALEX helps employees make sense of complex benefits information in plain language, using their individual needs and preferences to provide personalized guidance. It combines real-world claims data with information employees share about their unique circumstances and priorities to nudge them towards more informed benefits decisions.
That’s an important way to support your workforce on something as nuanced as GLP-1 coverage. For example, ALEX Home can help employees understand the difference between:
- A medication being covered versus only being covered for a specific condition
- Prior authorization versus simply getting a prescription from a doctor
- The medication’s list price versus what they’ll actually pay under their plan
- A coverage requirement versus a clinical recommendation
It can also help employees understand the tradeoffs involved in their broader benefits decisions—because GLP-1 use doesn’t exist in a vacuum. Employees might also be thinking about how they’ll pay for their medical plan, deductible, out-of-pocket maximum, HSA or FSA contributions, and other healthcare costs—in addition to their preferred weight loss drug.
The goal isn’t to tell employees whether they should take a particular medication. That’s a conversation between them and their healthcare provider. The goal is to help them understand how their benefits work so they can make informed decisions within that system.
The GLP-1 conversation is only getting started
If there’s one thing HR and benefits leaders can count on, it’s that the GLP-1 conversation will keep changing.
New medications are entering the market. Employer coverage strategies are evolving. Utilization is changing. And employers are continuing to weigh pharmacy costs against employee needs and potential long-term health outcomes.
That makes GLP-1 coverage an ongoing benefits strategy question—not just a prescription coverage question.
Employers that navigate it successfully will need more than a coverage policy. They’ll also need a way to help employees understand that policy when they actually need it. Whether your company is new to covering GLP-1s, offers limited coverage, or is deciding to drop coverage, employees will have questions.
With benefits decision support from ALEX, employees get clear, personalized guidance that helps them understand their options and make confident benefits decisions—while giving HR and benefits teams fewer repetitive questions to answer.
